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I investigate the contribution of pharmaceutical innovation to recent longevity growth in 
Germany and France. First, I examine the effect of the vintage of prescription drugs (and 
other variables) on the life expectancy and age-adjusted mortality rates of residents of 
Germany, using longitudinal, annual, state-level data during the period 2000-2007. The 
estimates imply that almost half of the 1.7-year increase in German life expectancy during the 
period 2000-2007 was due to the replacement of older drugs by newer drugs. Next, I examine 
the effect of the vintage of chemotherapy treatments on age-adjusted cancer mortality rates of 
residents of France, using longitudinal, annual, cancer-site-level data during the period 2002-
2006. The estimates imply that chemotherapy innovation accounted for at least one-sixth of 
the decline in French cancer mortality rates, and may have accounted for as much as half of 
the decline. 
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 I.  Introduction 
 
Longevity increase is an important part of economic growth and development.  Nordhaus 
(2002) estimated that, “to a first approximation, the economic value of increases in longevity 
over the twentieth century is about as large as the value of measured growth in non-health goods 
and services” (p. 17).  Murphy and Topel (2005) observed that “the historical gains from 
increased longevity have been enormous. Over the 20th century, cumulative gains in [U.S.] life 
expectancy were worth over $1.2 million per person for both men and women. Between 1970 
and 2000 increased longevity added about $3.2 trillion per year to national wealth, an uncounted 
value equal to about half of average annual GDP over the period.”  In its Human Development 
Reports, the United Nations Development Program ranks countries by their value of the Human 
Development Index, which is based on life expectancy at birth as well as on the adult literacy 
rate and per capita GDP.   
Since the 1950s, economists have recognized that, in the long run, the rate of economic 
growth is determined by (indeed equal to) the rate of technological progress.  In neoclassical 
growth models developed by Nobel laureate Robert Solow (1956, 1957) and colleagues, an 
economy will always converge towards a steady state rate of growth, which depends only on the 
rate of technological progress.   
In early models of economic growth, the rate of technological progress was assumed to 
be given, or exogenous: technological progress was regarded as “manna from heaven.”  
Economists began to relax this clearly unrealistic assumption in the 1980s, by developing so-
called “endogenous growth models.”  In Paul Romer’s (1990) model, “growth…is driven by 
technological change that arises from intentional [R&D] investment decisions made by profit-
maximizing agents.”
1  Jones (1998) argues that “technological progress [is] the ultimate driving 
force behind sustained economic growth” (p.2), and that “technological progress is driven by 
research and development (R&D) in the advanced world” (p. 89).   
Technological change may be either disembodied or embodied.  Suppose firm X invests 
in R&D, and that this investment results in a valuable discovery.  If the technological advance is 
disembodied, consumers and other firms could benefit from the discovery without purchasing 
                                                 
1 Growth may also be driven by technological change arising from R&D investment by public organizations, e.g. the 
National Institutes of Health. 
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firm X’s goods or services; they could benefit just by reading or hearing about the discovery.  
However, if the technological advance is embodied, consumers and other firms must purchase 
firm X’s goods or services to benefit from its discovery.  Solow (1960, p 91): argued that “many 
if not most innovations need to be embodied in new kinds of durable equipment before they can 
be made effective.  Improvements in technology affect output only to the extent that they are 
carried into practice either by net capital formation or by the replacement of old-fashioned 
equipment by the latest models…”
2   Romer also assumes that technological progress is 
embodied in new goods: “new knowledge is translated into goods with practical value,” and “a 
firm incurs fixed design or research and development costs when it creates a new good. It 
recovers those costs by selling the new good for a price that is higher than its constant cost of 
production.”  Grossman and Helpman (1993) argued that “innovative goods are better than older 
products simply because they provide more ‘product services’ in relation to their cost of 
production.”  Bresnahan and Gordon (1996) stated simply that “new goods are at the heart of 
economic progress,”  and Bils (2004) said that “much of economic growth occurs through 
growth in quality as new models of consumer goods replace older, sometimes inferior, models.” 
When technological progress is embodied in new goods, the welfare of consumers (and 
the productivity of producers) depends on the vintage of the goods (or inputs) they purchase.  In 
this context, “vintage” refers to the year in which the good was first produced or sold.  For 
example, the vintage of the drug simvastatin is 1993: that is the year it was approved by the 
FDA, and first sold.  Solow was the first economist to develop a growth model that distinguished 
between vintages of (capital) goods.
  In Solow's model, new capital is more valuable than old 
capital because--since capital is produced based on known technology, and technology improves 
with time--new capital will be more productive than old capital.
3  A number of econometric 
studies (Bahk and Gort (1993), Hulten (1992), Sakellaris and Wilson (2004)) have shown that 
manufacturing firms using later-vintage equipment have higher productivity.   
The extent to which the welfare of consumers or the productivity of producers depends 
on the vintage of the goods they purchase should depend on the research intensity of those 
goods.  The greater the research intensity of the goods, the greater the impact of their vintage on 
consumer welfare and producer productivity.  According to the National Science Foundation, the 
                                                 
2 We hypothesize that innovations may be embodied in nondurable goods (e.g. drugs) and services as well as in 
durable equipment. 
3 http://en.wikipedia.org/wiki/Exogenous_growth_model  
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pharmaceutical and medical devices industries are the most research intensive industries in the 
economy.
4 
In the next section, I will investigate the effect of the vintage of prescription drugs (and 
other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany, 
using longitudinal, annual, state-level data during the period 2000-2007.  The analysis will be 
based on data on the utilization of over 600 active ingredients in a variety of drug classes, which 
account for about 250 million prescriptions (43% of all prescriptions in Germany) per year. 
In the following section, I will investigate the effect of the vintage of chemotherapy 
treatments on age-adjusted cancer mortality rates of residents of France, using longitudinal, 
annual, cancer-site (breast, colon, lung, etc.) -level data during the period 2002-2006.
5  The 
analysis will be based on data on the utilization of 11 cancer drugs by about 4000 cancer patients 
per year. 
 
II.   Germany longevity 
 
A.   Econometric model 
 
  I will estimate models of the following form: 
 
OUTCOMEst =  VINTAGEst +  Xst + s + t + st               (1)     
 
where OUTCOME is one of the following variables: 
LEst   = life expectancy at birth in state s in year t (s = 1,…,16; t = 
2000,…,2007) 
ln_AAMORTst  = the log of the age-adjusted mortality rate in state s in year t
6 
 
                                                 
4 In 1997, “medical substances and devices firms had by far the highest combined R&D intensity at 11.8 
percent,…well above the 4.2-percent average for all 500 top 1997 R&D spenders combined. The information and 
electronics sector ranked second in intensity at 7.0 percent.”  The pattern of 1997 R&D spending per employee is 
similar to that for R&D intensity, with medical substances and devices again the highest at $29,095 per employee. 
Information and electronics is second at $16,381. Combined, the top 500 1997 R&D firms spent $10,457 per 
employee. 
5 Cancer was the cause of about 30% of deaths in France in 2006. 
6 Age-adjusted death rates are weighted averages of age-specific death rates, where the weights represent a fixed 
population by age. They are used to compare relative mortality risk among groups and over time. An age-adjusted 
rate represents the rate that would have existed had the age-specific rates of the particular year prevailed in a 
population whose age distribution was the same as that of the fixed population. 
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VINTAGE is one of the following variables: 
FDA_YEARst   = the (weighted) mean FDA approval year of ingredients contained in 
prescriptions consumed in state s in year t 
POST1990%st  = the percent of prescriptions consumed in state s in year t that 
contained ingredients approved by the FDA after 1990 
POST1995%st  = the percent of prescriptions consumed in state s in year t that 
contained ingredients approved by the FDA after 1995 
 
and X includes a subset of the following variables: 
ln_GDPst  = the log of GDP per person in state s in year t 
UNEMPst  = the unemployment rate in state s in year t 
ln_N_RXst  = the log of the number of prescriptions per person in state s in 
year t 
ln_NOTIF_DISEASESst  = the log of the number of notifiable diseases per 100,000 persons 
in state s in year t 
ln_AIDSst  = the log of the number of new AIDS cases per 100,000 persons in 
state s in year t 

s and t represent state fixed effects and year fixed effects, respectively.  Due to the inclusion of 
these effects, eq. (1) is a difference-in-differences model.  A significant negative drug vintage 
coefficient () in a model in which the dependent variable is life expectancy would indicate that 
states that had above-average increases in drug vintage had above-average increases in life 
expectancy, controlling for other regressors. 
Eq. (1) will be estimated by weighted least squares (WLS), weighting by popst, state s’s 
population in year t.  The estimation procedure will account for clustering of disturbances within 
states.   
 
The drug vintage measure FDA_YEAR will be constructed as follows: 
 
FDA_YEARst   = d N_RXdst APP_YEARd  




N_RXdst   = the number of prescriptions for drug d in state s in year t 




The drug vintage measure POST1990% will be constructed as follows: 
 
POST1990%st   = d N_RXdst APP_YEAR_GT_1990d  
                      d N_RXdst 
where 
APP_YEAR_GT_1990d   = 1 if the active ingredient of drug d was first approved by the FDA 
after 1990 
   = 0 otherwise 
 
The drug vintage measure POST1995% will be constructed as follows: 
 
POST1995%st   = d N_RXdst APP_YEAR_GT_1995d  
                      d N_RXdst 
where 
APP_YEAR_GT_1995d   = 1 if the active ingredient of drug d was first approved by the FDA 
after 1995 
   = 0 otherwise 
 
B.   Data and descriptive statistics 
 
Pharmaceutical data.  Data on the number of prescriptions, by drug, state, and year (N_RXdst) 
were obtained from the IMS Health National Prescription Analysis database 
(http://www.imshealth.de/sixcms/detail.php/375), which covers more than 99% of prescriptions 
reimbursed by German Sick Funds. It does not contain drugs used in a hospital, drugs completely 
paid out-of-pocket, and drugs prescribed for members of private health insurance companies 
(approximately 10% of the German population, particularly high-income employees, self-
                                                 
7 If drug d contains 2 or more active ingredients, APP_YEARd is the mean of the years in which the active 
ingredients of drug d were first approved by the FDA. 
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employed persons, military, and government officials).  We were unable to obtain data on all 
drugs sold in Germany.  Data were available for drugs included in the following drug classes
8: 
  Cardiovascular (C***)  
  Oncology (A04A, L***, B03A, B03C, V03D)  
  Parkinson (N04A)  
  Alzheimer/Dementia (N07D)  
  Antidiabetics (A10*)  
  Asthma/COPD (R03*)  
  NSAID/Coxibs (M01A)  
 
Appendix Table 1 compares 2008 data from our sample of drugs to data on all drugs dispensed 
in the Statutory Health Insurance system.  Overall, our dataset provides information on about 250 
million prescriptions per year for over 600 active ingredients, which account for 43% of total 
prescriptions and about 50% of total drug expenditure.   
Data on the initial year of FDA approval of active ingredients (APP_YEARd) were 
obtained from the Food and Drug Administration’s Drugs@FDA database 
(http://www.fda.gov/Drugs/InformationOnDrugs/ucm079750.htm).
9  We were able to determine 
the initial FDA approval year of products accounting for over 80% of the prescriptions in our 
sample. 
Table 1 shows data on the top 25 drugs in our sample, ranked by the number of 
prescriptions during 2000-2008.  Figure 1 shows data on the vintage distribution of prescriptions 
consumed during the period 2000-2008: it shows the percent of prescriptions consumed during 
2000-2008 that were for drugs approved after year t (t = 1940,...,2010).  About 75% of 
prescriptions were for drugs approved after 1975, 50% were for drugs approved after 1986, and 
25% were for drugs approved after 1993. 
Age-adjusted mortality and life expectancy data.  We will analyze two different measures of 
longevity: the age-adjusted mortality rate, and life expectancy at birth.  The Information System 
of the Federal Health Monitoring (http://www.gbe-bund.de/) provides data on age-adjusted 
mortality rates, by state and year.  It also provides time-series data on life expectancy in 
Germany as a whole, but not life expectancy by state.  However, it provides data on age-specific 
                                                 
8 European Pharmaceutical Market Research Association (EphMRA) drug classification codes are shown in 
parentheses.  The EphMRA classification is a modified modified version of the ATC classification.  See 
http://www.ephmra.org/classification/anatomical-classification.aspx. 
9 The U.S. is the country in which many drugs are first launched.  Also, it is difficult to obtain data on the date at 






1 DICLOFENAC 167.7 1993
2 METOPROLOL 108.0 1978
3 IBUPROFEN 93.8 1974
4 METFORMIN 65.3 1995
5 BISOPROLOL 62.8 1992
6 ENALAPRIL 58.8 1985
7 SIMVASTATIN 55.4 1991
8 FUROSEMIDE 50.8 1966
9 SALBUTAMOL 44.6 1981
10 RAMIPRIL 41.7 1991
11 CAPTOPRIL 40.6 1981
12 AMLODIPINE 40.0 2009
13 VERAPAMIL 36.4 1981
14 THEOPHYLLINE 35.0 1970
15 GLIBENCLAMIDE 32.5 1984
16 TORASEMIDE 32.1 1993
17 LISINOPRIL 29.0 1987
Table 1
Top 25 drugs in sample, ranked by number of prescriptions during 2000‐2008
18 INSULIN HUMAN BASE/INSULIN HUMAN ISOPHANE 28.4 .
19 ISOSORBIDE DINITRATE 28.1 1968
20 HYDROCHLOROTHIAZIDE 27.3 1959
21 NIFEDIPINE 26.8 1981
22 HYDROCHLOROTHIAZIDE/TRIAMTERENE 24.4 1961.5
23 HYDROCHLOROTHIAZIDE/RAMIPRIL 24.1 1975
24 NITRENDIPINE 23.5 .
25 ISOSORBIDE MONONITRATE 22.9 1991
7Figure 1
% of prescriptions consumed  during 2000‐2008  that were for drugs 
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mortality rates by state and year, from which life expectancy by state and year can be 
calculated.
10   
Data on life expectancy at birth during 2000-2007 in selected states are shown in Figure 2.  The 
rate of increase of life expectancy varied across states and over time.  In 2000, Saarland’s life 
expectancy was higher than Mecklenburg-Vorpommern’s; in 2007, it was slightly lower.  In 
2000, Schleswig-Holstein’s life expectancy was slightly higher than Berlin’s; in 2007, it was 
lower.   
Data on other variables.  Data on population, the number of notifiable diseases per 100,000 
persons,
11 and on the number of new AIDS cases per 100,000 persons, by state and year, were 
also obtained from The Information System of the Federal Health Monitoring.  Data on GDP per 
person and the unemployment rate, by state and year, were obtained from Eurostat’s regional 
statistics database (http://epp.eurostat.ec.europa.eu/portal/page/portal/eurostat/home).
12 
  Summary statistics, by year, are reported in Table 2.  The FDA_YEAR, POST1990%, 
and POST1995% statistics are weighted means, where the weight is the number of prescriptions.  
The other statistics (with the exceptions of the number of prescriptions and population) are 
weighted means, where the weight is the population.  The mean FDA approval year increased by 
3.0 years between 2000 and 2008.  The fraction of prescriptions that contained ingredients 
approved after 1990 increased from 32% in 2000 to 46% in 2008.  Life expectancy at birth 
increased by 1.8 years between 2000 and 2007. 
  The complete dataset used for estimation is shown in Appendix Table 2. 
 
C.   Empirical results 
 
  Estimates of models of life expectancy and the age-adjusted mortality rate are presented 
in Table 3.  We present estimates of 12 (= 2 × 3 × 2) different models.  We use two alternative 
outcome measures and three alternative drug vintage measures, and estimate models both 
excluding and including the vector of other explanatory variables (X in eq. (1)). 
                                                 
10 We verified that population-weighted averages of our state-level life expectancy estimates were very consistent 
with published estimates for Germany as a whole. 
11 In the Federal Republic of Germany, health authorities must be informed about cases of certain notifiable 
diseases, which are listed in the Infection Protection Act. Depending on the disease the suspicion, the disease and/or 
the death must be reported. (Source: www.rki.de).  Data on the incidence and prevalence of other diseases are not 
available. 



















































































































































































































































































































































2000 230 2.50 1983.0 32% 8% 82.2 78.1 886.0 7.8% 25,095 1.010 .
2001 241 2.59 1983.6 34% 10% 82.3 78.5 857.4 7.6% 25,664 0.954 298.4
2002 251 2.71 1983.9 35% 11% 82.5 78.5 858.3 8.4% 25,984 0.867 347.6
2003 265 2.86 1984.3 37% 12% 82.5 78.6 861.1 9.7% 26,222 0.844 308.8
2004 235 2.54 1984.7 39% 13% 82.5 79.2 811.1 10.6% 26,798 0.918 323.7
2005 241 2.60 1984.9 40% 12% 82.5 79.4 801.0 11.0% . 0.824 353.7
Table 2
Sample statistics by year
2005 241 2.60 1984.9 40% 12% 82.5 79.4 801.0 11.0% . 0.824 353.7
2006 245 2.64 1985.3 42% 13% 82.4 79.7 775.8 10.1% 28,182 0.813 361.7
2007 250 2.69 1985.6 44% 14% 82.3 79.9 766.0 8.6% . 0.733 541.0
2008 259 1986.0 46% 15%
11Model Regressor Estimate Z ProbZ Model Regressor Estimate Z ProbZ
1 fda_year 0.271 3.605 0.000 7 fda_year -0.022 -5.094 0.000
2 fda_year 0.326 3.153 0.002 8 fda_year -0.031 -4.814 0.000
2 lunits_pop -0.135 -0.293 0.769 8 lunits_pop -0.021 -0.641 0.521
2 unemp -0.014 -0.009 0.993 8 unemp -0.032 -0.284 0.777
2 lgdp -1.314 -1.667 0.095 8 lgdp 0.125 1.752 0.080
2 laids -0.027 -0.565 0.572 8 laids 0.002 0.531 0.595
2 lnotif -0.241 -2.064 0.039 8 lnotif 0.019 1.975 0.048
3 post1990 7.711 3.992 0.000 9 post1990 -0.646 -4.191 0.000
4 post1990 8.611 3.415 0.001 10 post1990 -0.814 -2.820 0.005
4 lunits_pop -0.115 -0.316 0.752 10 lunits_pop -0.024 -1.162 0.245
4 unemp -0.410 -0.272 0.786 10 unemp 0.008 0.067 0.946
4 lgdp -1.084 -1.527 0.127 10 lgdp 0.101 1.385 0.166
4 laids -0.015 -0.323 0.747 10 laids 0.001 0.230 0.818
4 lnotif -0.239 -1.981 0.048 10 lnotif 0.019 1.812 0.070
5 post1995 9.803 4.849 0.000 11 post1995 -0.821 -6.918 0.000
6 post1995 10.064 3.226 0.001 12 post1995 -0.957 -4.896 0.000
6 lunits_pop -0.206 -0.483 0.629 12 lunits_pop -0.015 -0.426 0.670
6 unemp -0.021 -0.013 0.990 12 unemp -0.030 -0.254 0.799
6 lgdp -0.925 -1.356 0.175 12 lgdp 0.087 1.325 0.185
6 laids -0.017 -0.402 0.688 12 laids 0.001 0.319 0.750
6 lnotif -0.154 -1.354 0.176 12 lnotif 0.011 1.189 0.234
Table 3
Estimates of models of life expectancy at birth and age-adjusted mortality rate, Germany, 2000-2007
Dependent variable: life expectancy at birth Dependent variable: log of age-adjusted mortality rate
The estimates are weighted least-squares estimates, weighting by state population. All equations include fixed 
state effects and fixed year effects. Standard errors are clustered within states.
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  In model 1, the dependent variable is life expectancy at birth, and there is only one 
explanatory variable: the (weighted) mean FDA approval year of ingredients contained in 
prescriptions consumed.  The coefficient on this variable is positive and highly significant (p-
value < .001).  This indicates that states with larger increases in drug vintage had larger increases 
in life expectancy.  However, the estimate of this coefficient may be biased if other determinants 
of life expectancy are correlated with drug vintage.   
  Model 2 includes other plausible determinants of life expectancy: the per capita quantity 
of drugs consumed, per capita income, the unemployment rate, the notifiable disease rate, and 
the AIDS case rate.  Controlling for these other variables increases the magnitude of the drug 
vintage coefficient by 20%.  The coefficients on the per capita quantity of drugs consumed, the 
unemployment rate, and the AIDS case rate are far from significant.  The coefficient on 
ln_NOTIF_DISEASES is negative and significant, which is to be expected: an increase in the 
number of notifiable diseases per 100,000 persons is associated with a decline in life expectancy.   
The coefficient on per capita income is negative and nearly significant (p-value=.095): 
states with high income growth had smaller longevity increases, ceteris paribus.  Some previous 
investigators have also found evidence of a non-monotonic or even inverse relationship between 
income and longevity.  Uchida et al (1992) found that “for [Japanese] females high income was 
the factor significantly decreasing life expectancy at 65 years of age in 1980.”  Hupfeld (2008) 
theoretically derived a non–monotonic relationship between income and longevity, based on 
heterogeneous elasticities of labor supply and otherwise standard assumptions. He analyzed this 
relationship empirically for pensioners in the public pension system in Germany, and find that 
“the relationship between income and life expectancy is indeed non–monotonic for major sub–
groups in the data.”  And Ruhm (2004) argued that “although health is conventionally believed 
to deteriorate during macroeconomic downturns, the empirical evidence supporting this view is 
quite weak and comes from studies containing methodological shortcomings that are difficult to 
remedy.  Recent research that better controls for many sources of omitted variables bias instead 
suggests that mortality decreases and physical health improves when the economy temporarily 
weakens.  This partially reflects reductions in external sources of death, such as traffic fatalities 
and other accidents, but changes in lifestyles and health behaviors are also likely to play a role.” 
  Models 3 and 4 are similar to models 1 and 2, but instead of FDA_YEAR, the measure of 
drug vintage is the fraction of prescriptions containing ingredients approved by the FDA after 
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1990 (POST1990%).  The estimates of these two models are qualitatively similar to the estimates 
of models 1 and 2.  The coefficient on POST1990% is positive and highly significant, and is 
larger when other factors are included than it is when they are excluded.   
  Models 5 and 6 use the third measure of drug vintage: the fraction of prescriptions 
containing ingredients approved by the FDA after 1995 (POST1995%).  Once again, the drug 
vintage coefficient is positive and significant, and larger (albeit by a smaller margin) when other 
factors are controlled for.  In this case, however, none of the coefficients on the other factors are 
close to being statistically significant. 
  The estimates of models 1-6 indicate that (1) there is a highly significant relationship 
across states between the increase in drug vintage and the increase in life expectancy, and (2) 
controlling for some other potentially important determinants of life expectancy, and changing 
the measure of drug vintage, has little effect on this relationship.  Models 7-12 are similar to 
models 1-6, but in these models the dependent variable is the log of the age-adjusted mortality 
rate.  The age-adjusted mortality rate and life expectancy at birth both depend on (are functions 
of) age-specific mortality rates, but they depend on them in different ways.  The estimates of 
models 7-12 indicate that (1) there is a highly significant relationship across states between the 
increase in drug vintage and the decline in the age-adjusted mortality rate, and (2) controlling for 
some other potentially important determinants of the age-adjusted mortality rate, and changing 
the measure of drug vintage, has little effect on this relationship. 
  The parameter estimates can be used to estimate how much of the 1.7-year increase in life 
expectancy during the period 2000-2007 was attributable to the increase in drug vintage, i.e. to 
the use of newer drugs.   These calculations are shown in the following table. 
Model 2  4  6 
Vintage measure  FDA_YEAR  post1990%  post1995% 
2000-2007 change in vintage measure () 2.6 12%  5% 
 0.326 8.611  10.064 
 *  0.8 1.0  0.5 
 
Model 2, based on the FDA_YEAR drug vintage measure, implies that use of newer drugs 
increased life expectancy at birth by 0.8 years (almost half of the actual increase in life 
expectancy) during the period 2000-2007.  Model 4, based on the POST1990% drug vintage 
measure, implies that use of newer drugs increased life expectancy by a larger amount: 1.0 years.  
14 
 
Model 6, based on the POST1995% drug vintage measure, implies that use of newer drugs 
increased life expectancy by a smaller amount: 0.5 years.  The mean of these three estimates is 
0.8 years. 
  The parameter estimates can also be used to obtain a rough assessment of the overall 
cost-effectiveness of pharmaceutical innovation.  We define the incremental cost-effectiveness 
ratio (ICER) as follows: 
ICER = change in lifetime drug expenditure due to pharmaceutical innovation 
                               change in life expectancy due to pharmaceutical innovation 
 





annual drug expenditure 
in constant 2000 €
1 
lifetime drug expenditure (= life 
expectancy * annual drug 
expenditure) 
2000  78.1  € 300  € 23,430 
2006 78.8
2  € 364  € 28,683 
change 0.7     € 5,253 
1: Source: 2009 OECD Health Database 
2: “Predicted” life expectancy in 2006 = LE2000 +  (VINT2006 – VINT2000) 
 
German life expectancy at birth was 78.1 years in 2000.  The mean of the estimates of  from 
models 2, 4, and 6 implies that the increase in drug vintage increased life expectancy by 0.7 
years between 2000 and 2006.  According to the 2009 OECD Health Database, per capita 
expenditure (in constant 2000 €) on prescription drugs increased from € 300 in 2000 to € 364 in 
2006.  Assuming that this increase was entirely due to use of newer drugs, pharmaceutical 
innovation increased lifetime drug expenditure by € 5,253.  The implied ICER is € 7512 (=  € 
5,253 / 0.70 years) per life-year.  This is a small fraction of leading economists’ estimates of the 
value of (willingness to pay for) an additional year of life.  Moreover, while use of newer drugs 
undoubtedly increases pharmaceutical expenditure, there is evidence that it reduces other 
medical expenditure (especially hospital expenditure (Lichtenberg (2009)), so the true ICER may 




III.   French cancer mortality 
 
Now I will investigate the effect of the vintage of chemotherapy treatments on mortality 
rates of French cancer patients, using longitudinal, annual, cancer-site (breast, colon, lung, etc.) 
level data during the period 2002-2006.   
Two types of statistics are used to measure cancer mortality: survival rates and mortality 
rates.  Survival rates are typically expressed as the proportion of patients alive at some point 
subsequent to the diagnosis of their cancer.  For example, the observed 5-year survival rate is 
defined as follows:  
 
5-year Survival Rate = Number of people diagnosed with cancer at time t alive at time 
t+5 / Number of people diagnosed with cancer at time t 
= 1 – (Number of people diagnosed with cancer at time t dead at time t+5 / Number of 
people diagnosed with cancer at time t) 
 
Hence, the survival rate is based on a conditional (upon previous diagnosis) mortality 
rate.  The second type of statistic is the unconditional cancer mortality rate: the number of 
deaths, with cancer as the underlying cause of death, occurring during a year per 100,000 
population.  
The outcome measure I will analyze is the unconditional (age-adjusted) cancer mortality 
rate.  Longitudinal, cancer-site level data on conditional mortality (or survival) are not available 
during the period for which we have chemotherapy treatment data (2002-2006), although they 
are available for earlier years.
13  Moreover, Welch et al (2000) argued that “while 5-year survival 
is a perfectly valid measure to compare cancer therapies in a randomized trial, comparisons of 5-
year survival rates across time (or place) may be extremely misleading. If cancer patients in the 
past always had palpable tumors at the time of diagnosis while current cancer patients include 
those diagnosed with microscopic abnormalities, then 5-year survival would be expected to 
increase over time even if new screening and treatment strategies are ineffective.”  
Consequently, Welch et al (2000) concluded that “to avoid the problems introduced by changing 
patterns of diagnosis…progress against cancer [should] be assessed using [unconditional] 
population-based mortality rates.” 
                                                 
13 The Eurocare 3 and Eurocare 4 databases (http://www.eurocare.it/Home/tabid/36/Default.aspx) provide data on 
survival rates of French cancer patients diagnosed during the following periods: 1983-1985, 1986-1988, 1989-1991, 
1992-1994, and 1995-1999.   
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A.   Econometric model 
 
  I will estimate models of the following form: 
 
ln (AAMORT)st =  VINTAGEst + s + t + st               (2)     
 
where  
ln (AAMORTst)  = the log of the age-adjusted mortality rate from cancer at site s in year 
t (s=1,…,24; t=20002,…,2006) 
 
VINTAGE is one of the following variables: 
LAUNCH_YEARst   = the (weighted) mean world launch year of chemotherapy 
treatments for cancer site s in year t 
POST1985%st  = the percent of chemotherapy treatments for cancer site s in year t 
that contained ingredients launched after 1985 
POST1990%st  = the percent of chemotherapy treatments for cancer site s in year t 
that contained ingredients launched after 1990 
 
s and t represent cancer-site fixed effects and year fixed effects, respectively.  A significant 
negative drug vintage coefficient () in eq. (2) would indicate that cancer sites that had above-
average increases in drug vintage had above-average reductions in the age-adjusted mortality 
rate. 
Eq. (2) will be estimated by weighted least squares, weighting by the mean of each 
cancer site’s mortality rate during the entire sample period ((1 / T) ∑t AAMORTst).  The 
estimation procedure will account for clustering of disturbances within cancer sites.   
The drug vintage measure LAUNCH_YEAR will be constructed as follows: 
 
LAUNCH_YEARst   = c N_PATIENTScst INTRO_YEARc  
               c N_PATIENTScst 
where 
N_PATIENTScst   = the number of patients with cancer at site s who were treated with 
chemotherapy agent c in year t 
INTRO_YEARc   = the year in which chemotherapy agent c was first launched 
 
The drug vintage measure POST1985% will be constructed as follows: 
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POST1985%st   = c N_PATIENTScst INTRO_YEAR_GT_1985c  
                        c N_PATIENTScst 
where 
INTRO_YEAR_GT_1985c   = 1 if chemotherapy agent c was first launched after 1985 
   = 0 otherwise 
POST1990% will be constructed in a similar fashion. 
  The only explanatory variable in eq. (2) (aside from the cancer-site fixed effects and year 
fixed effects) is chemotherapy vintage.  Cancer mortality rates are also likely to depend on other 
cancer-site-specific, time-varying variables, and these might be correlated with drug vintage.  In 
particular, mortality rates are likely to depend on (1) incidence rates, and (2) non-pharmaceutical 
innovation.  Unfortunately, data on cancer incidence and non-pharmaceutical innovation, by 
cancer site, are not available for France during the period covered by our chemotherapy data.
14  
However, in a recent paper based on U.S. cancer data during the period 1996-2006, Lichtenberg 
(2010) found that, although pharmaceutical innovation, non-pharmaceutical innovation, and 
incidence all had significant effects on cancer mortality rates, controlling for the latter two 
variables had virtually no effect on the pharmaceutical innovation coefficient. 
 
B.   Data and descriptive statistics 
 
Pharmaceutical data.  Data on the number of patients with cancer at site s who were treated with 
chemotherapy agent c in year t (N_PATIENTScst) were obtained from IMS Health’s Oncology 
Analyzer database.
15  IMS collected data on the frequency with which 11 chemotherapy agents 
were administered to a sample of about 20,000 French cancer patients during the period 2002-
2006.  As the following table shows, the size of the sample increased over time: 






                                                 
14 Data on non-pharmaceutical innovation are not available for any period.  According to the European Cancer 
Observatory, annual data on cancer incidence, by site, are only available during the period 1983-1997 (http://eu-
cancer.iarc.fr/16-table.html,en). 
15 If a patient was treated with n chemotherapy agents, that patient would be counted n times. 
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The eleven drugs (ranked by frequency of use), and the years in which they were launched, are 
shown in the following table: 
frequency rank  chemotherapy agent world launch year
1 doxorubicin  1971 
2 epirubicin  1984 
3 gemcitabine  1995 
4 carboplatin  1985 
5 docetaxel  1995 
6 paclitaxel  1992 
7 vinorelbine  1989 
8 imatinib  2001 
9 capecitabine 1998 
10 temozolomide 1999 
11 pemetrexed  2004 
 
Table 4 shows the number of sample patients during 2002-2006, by cancer site.  The two cancer 
sites with the largest number of patients were breast and lung.  The three chemotherapy agents 
most frequently used to treat each of the five cancer sites with the largest numbers of patients are 
shown in Table 5.
16   
Mortality data.  Data on age-adjusted
17 mortality rates, by cancer site, were obtained from the 
Centre d'épidémiologie sur les causes médicales de décès, Institut national de la santé et de la 
recherche médicale (http://www.cepidc.vesinet.inserm.fr/inserm/html/index2.htm). 
  The complete dataset used for estimation is shown in Appendix Table 3. 
 
C.   Empirical results 
 
  Estimates of chemotherapy vintage coefficients () from different versions of eq. (2) are 
shown in Table 6.  The first three estimates are based on the full set of cancer sites.  In model 1, 
the vintage measure is the (weighted) mean world launch year of chemotherapy treatments.  The 
coefficient on LAUNCH_YEAR is negative and highly significant (p-value = .008).  This 
indicates that cancer sites for which there were larger increases in chemotherapy vintage had 
larger reductions in the age-adjusted mortality rate.  A 10-year increase in mean drug vintage is 
estimated to reduce the age-adjusted mortality rate by about 6%.  Models 2 and 3 indicate that 
                                                 
16 Only two drugs were used to treat Hodgkin’s disease among sample patients. 
17 The age distribution of the French population in 2002 was used to obtain age-adjusted mortality rates. 
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Chemotherapy agents most frequently used to 
treat French cancer patients during 2002-2006, 
by cancer site
21Model Regressor Estimate Stderr LowerCL UpperCL Z ProbZ
1 Launch_Year -0.006 0.002 -0.011 -0.002 -2.665 0.008
2 post1985% -0.122 0.034 -0.187 -0.056 -3.618 0.000
3 post1990% -0.107 0.029 -0.165 -0.049 -3.644 0.000
4 Launch_Year -0.008 0.002 -0.011 -0.005 -5.035 0.000
5 post1985% -0.094 0.028 -0.150 -0.039 -3.328 0.001




Estimates of models of age-adjusted cancer mortality rate, France, 2002-2006
The estimates are weighted least‐squares estimates, weighting by the mean of each cancer 
site’s mortality rate during the entire sample period ((1 / T) ∑t AAMORTst).  All equations 




the change in the age-adjusted mortality rate was also inversely correlated with the other two 
measures of chemotherapy vintage (POST1985% and POST1990%).  Model 2 implies that the 
mortality rate would be about 12% lower if only post-1985 drugs were used than it would be if 
only pre-1986 drugs were used. 
As noted earlier, these are weighted least-squares estimates, where the weight is the mean 
of each cancer site’s mortality rate during the entire sample period.  As shown in Figure 3, the 
mortality rate for lung cancer is far higher than it is for other types of cancer.  Therefore, the 
estimates of models 1-3 give a great deal of weight to the lung cancer data.  Models 4-6 are 
estimates based on the full set of cancer sites except lung cancer.  All three drug vintage 
coefficients remain negative and highly significant when lung cancer is excluded from the 
sample.   Excluding lung cancer increases the magnitude of  by about 25% in models 4 and 6, 
but reduces the magnitude of  by about 25% in model 5. 
According to Eurostat,
18 the age-adjusted mortality rate from malignant neoplasms in 
France declined by 6% between 2002 and 2006.  The parameter estimates can be used to 
estimate how much of this decline was attributable to the increase in drug vintage, i.e. to the use 
of newer chemotherapy agents.   The decline in the age-adjusted mortality rate attributable to the 
2002-2006 increase in drug vintage is  * , where  = (V2006 – V2002) and Vt = mean drug 
vintage in year t.   
There are two different data sources from which we can calculate .  The first is the IMS 
Oncology Analyzer database.  As noted above, this contains data on the use of 11 cancer drugs 
by about 4000 patients per year during the period 2002-2006.  The second data source is the 
Groupement pour l 'Elaboration et la Réalisation de Statistiques (GERS, http://www.gie-
gers.fr/index.php3).  This source provides annual data on the use of all (106) cancer drugs by all 
cancer patients in France during the period 1998-2007.
19 
Table 7 shows a comparison of chemotherapy vintage measures derived from the IMS 
Oncology Analyzer and GERS databases.
20  The GERS estimates of the 2002-2006 increase in 
mean vintage are about three times as large as the IMS estimates.  For example, the GERS data 
                                                 
18 Source: Eurostat hlth_cd_asdr dataset. 
19 GERS provides data on the quantity of each drug, by year, but not by cancer site. 
20 The GERS vintage measures are based on the year each drug was first commercialized in France, rather than the 
world launch year, which is not available for all drugs.  For the 11 drugs for which both dates were available, there 
is generally a close correspondence between the two dates.  For 8 out of the 11 drugs, the year of commercialization 
in France was 0-2 years after the world launch year. 




























IMS GERS IMS GERS IMS GERS IMS GERS
1998 109,507,687 1978.3 30% 10%
1999 111,235,927 1978.9 32% 15%
2000 115,983,400 1979.6 35% 19%
2001 124,227,347 1980.7 38% 25%
2002 2713 138,344,711 1985.6 1982.1 47% 44% 37% 32%
2003 3195 150,057,851 1986.2 1984.0 50% 53% 39% 41%
2004 3767 156,556,767 1986.3 1985.7 49% 60% 43% 49%
2005 5063 157,138,449 1987.3 1986.8 53% 64% 46% 57%
2006 5217 167,624,451 1987.4 1987.6 53% 67% 46% 61%
2007 175,757,939 1988.1 69% 63%
2006 - 2002 1.8 5.5 7% 23% 9% 29%
Table 7
Comparison of chemotherapy vintage measures derived from IMS Oncology Analyzer and GERS 
databases
LAUNCH_YEAR POST1985% POST1990% N
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imply that mean LAUNCH_YEAR increased by 5.5 years, while the IMS data imply that it 
increased by only 1.8 years. 
Estimates of the decline in the age-adjusted mortality rate attributable to the 2002-2006 
increase in drug vintage based on both the IMS data and the GERS data are shown in the 
following table. 
Model 1  2  3 
Vintage measure  LAUNCH_YEAR POST1985%  POST1990%
 -0.006 -0.122  -0.107 
           
   IMS Oncology Analyzer database 
2002-2006 change in vintage measure () 1.8 7%  9% 
 -0.011 -0.008  -0.010 
           
   GERS database 
2002-2006 change in vintage measure () 5.5 23%  29% 
 -0.034 -0.028  -0.031 
 
The estimates of  derived from the IMS database imply that the increase in drug vintage 
reduced the age-adjusted cancer mortality rate by about 1% during 2002-2006, which is about 
1/6 of the total decline in the mortality rate.  The estimates of  derived from the GERS database 
imply that the increase in drug vintage reduced the age-adjusted cancer mortality rate by about 
3% during 2002-2006, which is about half of the total decline in the mortality rate.   
 
IV.   Summary 
 
Longevity increase is an important part of economic growth and development.  In the 
long run, the rate of economic growth is determined by the rate of technological progress, which 
is generated by private and public R&D investment.   Most technological progress is embodied 
in new goods.  Therefore, the welfare of consumers (and the productivity of producers) depends 
on the vintage of the goods (or inputs) they purchase, especially when those goods are R&D-
intensive.  The pharmaceutical and medical devices industries are the most R&D-intensive 
industries in the economy 
In this paper, I have investigated the contribution of pharmaceutical innovation to recent 
longevity growth in Germany and France.  First, I examined the effect of the vintage of 
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prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of 
residents of Germany, using longitudinal, annual, state-level data during the period 2000-2007.  
Then, I examined the effect of the vintage of chemotherapy treatments on age-adjusted cancer 
mortality rates of residents of France, using longitudinal, annual, cancer-site-level data during 
the period 2002-2006.   
The analysis of Germany was based on data on the utilization of over 600 active 
ingredients, which account for about 250 million prescriptions per year.  I found that states with 
larger increases in drug vintage had larger increases in life expectancy.  Controlling for some 
other potentially important determinants of life expectancy (the per capita quantity of drugs 
consumed, per capita income, the unemployment rate, the notifiable disease rate, and the AIDS 
case rate) and changing the measure of drug vintage, had little effect on the relationship between 
drug vintage and life expectancy.  There was also a highly significant relationship across states 
between the increase in drug vintage and the decline in the age-adjusted mortality rate.   
German life expectancy at birth increased by 1.7 years during the period 2000-2007.  The 
estimates imply that almost half of this increase was due to the replacement of older drugs by 
newer drugs.  My estimate of the cost per life-year gained from the use of newer drugs is a small 
fraction of leading economists’ estimates of the value of (willingness to pay for) an additional 
year of life.   
The analysis of France was based on data on the utilization of 11 cancer drugs by about 
4000 cancer patients per year.  I found that cancer sites for which there were larger increases in 
chemotherapy vintage had larger reductions in the age-adjusted mortality rate.  A 10-year 
increase in mean drug vintage was estimated to reduce the age-adjusted mortality rate by about 
6%.  Changing the measure of drug vintage, and excluding lung cancer—by far the largest cause 
of cancer deaths in France—had little effect on the relationship between drug vintage and the 
cancer mortality rate.  My estimates implied that chemotherapy innovation accounted for at least 
one-sixth of the decline in French cancer mortality rates during 2002-2006, and may have 
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Overall market 608.1 26677 44 259 7748 30 43% 29%
A01 Stomalogical preparations 1.2 14 11
A02 Ulcer therapeutics 25.3 1139 45
A03 Spasmolytics 8.5 115 14
A04 Antiemetics and agents for 
sickness 2.1 73 35 2 43 20 101% 59%
A05 Bilious and liver therapy 0.4 31 76
A06 Laxatives 2.2 42 19
A07 Antidiarrheals 4.4 187 42
A09 Digestives, including enzymes 0.7 58 82
A10 Antidiabetics 29.5 1691 57 30 1084 37 101% 64%
A11 Vitamins 3.2 76 24
A12 Minerals 3.1 78 25
A16 Enzyme substitute 0.1 183 1833
B01 Antithrombotical agents 15.0 862 57
B02 Antihemorrhagics 0.3 112 373






B03 Antianemic combinations 3.6 372 103 1 233 269 24% 63%
B05 Blood substitute drugs and 
perfusion solutions 3.1 161 52
C01 Cardiac therapeutics 11.7 279 24 12 132 11 104% 47%
C02 Antihypertensives 4.3 257 60 4 78 18 100% 30%
C03 Diuretics 20.7 399 19 21 151 7 102% 38%
C04 Peripheral vasodilators 1.6 62 39 2 25 14 108% 41%
C05 Vasoprotectives 1.5 30 20 0 1 19 3% 3%
C06 Antihypotonics 0.2 5 25 0 101 1498 34% 2016%
C07 Beta‐receptor blocker 35.0 691 20 35 253 7 100% 37%
C08 Calcium antagonists 17.4 331 19 18 135 8 103% 41%
C09 Angiotensin inhibitor 46.2 1889 41 47 1109 24 101% 59%
C10 Antilipemics 16.9 736 44 17 433 25 101% 59%
D01 Antifungals (topical) 4.2 90 21
D02 Agents for skin protection 0.8 9 11
D03 Wound treatment agents 0.5 6 12
D04 Antipruriginous agents 0.8 6 7
D05 Antipsoriatics 0.8 70 87
D06 Antiinfectives (dermatological) 2.5 49 20
D07 Corticosteroids (dermatological) 9.1 163 18
D08 Antiseptics and disinfective 





































D09 Medical bandages 0.5 19 38
D10 Anti‐acne preparations 1.7 41 24
D11 Other dermatological 
preparations 1.4 39 28
G01 Gynaecological antiinfectivs 1.5 22 15
G02 Other gynecologicals 0.4 15 38
G03 Sexual hormones 12.8 424 33
G04 Urological drugs 6.2 313 51
H01 Pituitary/hypothalamic hormones 0.4 324 810
H02 Corticosteroids (systemic) 7.9 155 20
H03 Thyroids therapeutics 20.0 316 16
H05 Calcium homoeostasis 0.1 58 583
J01 Antibiotics 39.1 753 19
J02 Antifungals 0.6 68 113
J05 Antivirals 1.6 663 414
J06 Immune sera and J06 Immune sera and 
immunoglobulins 0.3 185 617
J07 Vaccines 1.3 134 103
L01 Antineoplastic agents 1.0 843 843 1 619 612 101% 73%
L02 Hormone antagonists 1.5 578 385 2 442 285 103% 77%
L03 Immunostimulants 1.2 1156 964 1 787 1163 56% 68%
L04 Immunosuppressants 2.1 1370 652 1 464 310 71% 34%
M01 Antiphlogistics/anti‐
inflammatory drugs 37.4 607 16 35 163 5 94% 27%
M02 Anti‐inflammatory agens (topical) 1.3 16 12
M03 Muscle relaxants 4.0 134 33
M04 Gout agents 6.5 94 14
M05 Osteoporosis agents 3.0 417 139
N01 Anesthetics 0.3 8 26
N02 Analgesics 33.9 1398 41
N03 Antiepileptics 7.9 630 80
N04 Anti parkinson drugs 5.7 499 87 5 330 64 91% 66%
N05 Psycholeptics 25.4 1103 43
N06 Psychoanaleptics 20.7 1159 56
N07 Anti vertiginous and addiction 





































P01 Agents againt protozoa 0.7 14 20
P02 Anthelmintics 0.3 8 25
P03 Insecticides and repellents 0.7 14 20
R01 Rhinologic drugs 11.1 85 8
R02 Throat and pharynx therapeutics 0.6 4 7
R03 Anti‐asthma medication 24.3 1458 60 24 953 40 99% 65%
R04 Chest ointment and other 
inhalants 0.4 3 7
R05 Cough and cold preparations 17.5 181 10
R06 Antihistamines 3.1 73 23
S01 Ophthalmic drugs 15.6 448 29
S02 Otologicals 1.3 19 15
S03 Ophthalmic drugs/otologicals 0.7 12 17
V01 Allergenes 0.9 300 333
V03 Antidotes/other agents 0.6 114 190 0 16 157 17% 14%


























































































































































































































































































































































































































Baden‐Wuerttemberg 2000 25.2 1983.3 33% 8% 2.41 79.2 810.6 10.49 4.1% 28,343 0.32
Baden‐Wuerttemberg 2001 26.6 1983.9 36% 10% 2.52 79.6 782.9 10.56 3.7% 29,308 284.1 0.36
Baden‐Wuerttemberg 2002 27.4 1984.3 37% 11% 2.58 79.7 778.0 10.63 4.4% 29,350 257.9 0.23
Baden‐Wuerttemberg 2003 28.9 1984.6 38% 13% 2.71 79.8 783.1 10.68 5.7% 29,530 229.8 0.19
Baden‐Wuerttemberg 2004 26.1 1985.1 41% 14% 2.44 80.5 725.9 10.71 6.6% 29,845 230.3 0.27
Baden‐Wuerttemberg 2005 26.6 1985.1 42% 12% 2.48 80.6 721.7 10.73 7.0% 252.4 0.26
Baden‐Wuerttemberg 2006 27.1 1985.5 44% 13% 2.52 81.0 692.9 10.74 6.3% 31,427 279.9 0.17
Baden‐Wuerttemberg 2007 27.9 1985.9 46% 14% 2.60 81.1 687.0 10.75 4.9% 402.8 0.15
Baden‐Wuerttemberg 2008 29.0 1986.2 48% 15% 4.2%
Bayern 2000 30.0 1983.1 34% 8% 2.46 78.5 858.5 12.19 4.0% 29,487 0.48
Bayern 2001 31.8 1983.9 37% 10% 2.59 78.8 833.5 12.28 3.8% 30,090 234.4 0.42
Bayern 2002 32.5 1984.3 39% 11% 2.63 78.9 831.6 12.36 4.5% 30,671 255.0 0.37
Bayern 2003 34.4 1984.6 40% 12% 2.77 79.0 834.5 12.40 6.1% 30,783 234.9 0.30
Bayern 2004 30.5 1985.0 43% 13% 2.46 79.7 783.4 12.43 6.8% 31,601 244.1 0.43
Bayern 2005 31.4 1985.2 44% 12% 2.52 79.7 780.5 12.46 7.0% 292.5 0.32
Bayern 2006 32.1 1985.6 46% 13% 2.57 80.0 762.8 12.48 6.5% 33,217 295.2 0.27
Bayern 2007 32.7 1985.9 48% 14% 2.61 80.2 744.3 12.50 5.3% 427.3 0.23
Bayern 2008 33.9 1986.3 50% 15% 4.2%
Berlin 2000 8.6 1982.8 30% 9% 2.54 78.0 879.0 3.38 14.4% 23,162 6.50
Berlin 2001 8.9 1983.3 32% 10% 2.63 78.4 855.2 3.39 15.1% 23,245 351.7 5.11
Berlin 2002 9.5 1983.7 34% 11% 2.79 78.2 866.3 3.39 15.6% 23,210 417.0 5.10
Berlin 2003 10.1 1984.0 35% 12% 2.99 78.5 857.4 3.39 18.0% 23,046 340.2 5.04
Berlin 2004 9.0 1984.3 37% 13% 2.65 79.1 814.7 3.39 19.1% 22,896 392.2 5.79
Berlin 2005 9.1 1984.5 38% 12% 2.70 79.2 802.1 3.39 19.2% 465.2 5.22
Berlin 2006 9.4 1985.0 40% 13% 2.77 79.5 774.7 3.40 18.7% 23,689 425.3 5.50
Berlin 2007 9.4 1985.5 43% 14% 2.77 79.9 752.6 3.41 16.3% 654.1 5.05
Berlin 2008 9.8 1986.0 46% 15% 15.1%
Brandenburg 2000 8.2 1983.2 31% 9% 3.16 77.1 965.6 2.60 16.3% 17,298 0.38
Brandenburg 2001 8.5 1983.7 33% 10% 3.29 77.5 933.5 2.60 16.9% 17,697 372.5 0.27
Brandenburg 2002 8.8 1984.2 35% 11% 3.39 77.6 934.1 2.59 16.9% 18,015 509.7 0.54
Brandenburg 2003 9.5 1984.7 37% 13% 3.69 77.6 931.5 2.58 18.3% 18,199 465.5 0.43
Brandenburg 2004 8.4 1985.2 39% 14% 3.27 78.2 875.5 2.57 19.2% 18,778 479.3 0.54
Brandenburg 2005 8.7 1985.3 40% 13% 3.38 78.6 853.9 2.56 18.1% 541.2 0.23
Brandenburg 2006 8.9 1985.6 42% 13% 3.47 78.8 837.9 2.55 16.5% 19,652 518.7 0.74
Brandenburg 2007 9.0 1986.0 44% 14% 3.53 79.0 825.3 2.54 13.8% 879.5 0.90
Brandenburg 2008 9.3 1986.5 47% 15% 11.5%
Bremen 2000 2.0 1982.5 30% 8% 2.96 77.4 883.8 0.66 10.0% 33,423 1.21
Bremen 2001 2.0 1982.9 32% 9% 3.05 77.9 849.4 0.66 8.7% 34,421 271.8 1.21













































































































































































































































































































































































































Bremen 2003 2.1 1983.2 33% 9% 3.23 78.1 863.3 0.66 11.4% 35,904 319.0 0.45
Bremen 2004 1.9 1983.4 35% 9% 2.85 78.6 820.8 0.66 14.6% 36,666 332.4 0.75
Bremen 2005 1.9 1983.7 37% 9% 2.93 78.7 812.7 0.66 16.5% 316.2 0.60
Bremen 2006 2.0 1984.1 38% 10% 2.96 79.2 777.4 0.66 14.4% 38,211 231.8 1.96
Bremen 2007 2.0 1984.4 40% 11% 3.05 79.0 778.3 0.66 11.9% 444.6 1.06
Bremen 2008 2.1 1984.8 42% 11% 9.5%
Hamburg 2000 4.5 1983.1 31% 8% 2.65 78.3 849.6 1.71 7.7% 42,422 4.27
Hamburg 2001 4.7 1983.5 33% 10% 2.72 78.7 820.7 1.72 7.0% 44,402 360.0 4.13
Hamburg 2002 4.8 1983.9 34% 11% 2.81 78.6 841.5 1.73 8.2% 44,908 466.2 4.05
Hamburg 2003 4.9 1984.1 35% 12% 2.85 78.8 829.6 1.73 9.6% 45,020 357.9 4.44
Hamburg 2004 4.4 1984.3 36% 12% 2.54 79.2 801.6 1.74 10.6% 45,724 369.7 4.55
Hamburg 2005 4.4 1984.5 37% 11% 2.52 79.5 782.9 1.74 10.4% 385.3 3.56
Hamburg 2006 4.4 1984.9 39% 12% 2.54 79.9 762.6 1.75 9.8% 48,611 509.7 3.03
Hamburg 2007 4.5 1985.3 41% 13% 2.55 80.0 753.2 1.76 8.9% 705.4 2.72
Hamburg 2008 4.6 1985.7 44% 14% 7.1%
Hessen 2000 16.2 1982.6 31% 7% 2.67 78.6 856.5 6.06 5.8% 30,223 1.54
Hessen 2001 17.0 1983.1 33% 9% 2.79 79.0 825.1 6.07 5.5% 31,203 224.2 1.45
Hessen 2002 17.4 1983.4 34% 10% 2.86 78.9 828.9 6.08 5.9% 31,407 242.0 1.28
Hessen 2003 18.2 1983.8 36% 11% 2.99 78.9 835.8 6.09 7.1% 32,151 228.8 1.10
Hessen 2004 16.4 1984.3 38% 12% 2.69 79.6 784.0 6.09 7.9% 32,641 224.1 1.23
Hessen 2005 16.7 1984.6 40% 12% 2.74 79.9 762.8 6.09 8.4% 244.4 1.15
Hessen 2006 16.9 1985.1 42% 13% 2.78 80.3 736.5 6.08 8.1% 34,369 243.7 1.00
Hessen 2007 17.0 1985.5 44% 13% 2.81 80.3 740.2 6.07 7.3% 425.3 0.64
Hessen 2008 17.5 1985.9 47% 15% 6.4%
Mecklenburg‐Vorpommern 2000 6.4 1983.1 31% 9% 3.59 76.4 1000.6 1.78 16.4% 16,860 0.17
Mecklenburg‐Vorpommern 2001 6.6 1983.8 34% 11% 3.74 76.9 958.8 1.77 18.5% 17,343 456.7 0.45
Mecklenburg‐Vorpommern 2002 6.8 1984.3 35% 12% 3.89 77.1 947.5 1.75 19.1% 17,624 739.0 0.40
Mecklenburg‐Vorpommern 2003 7.3 1985.0 38% 14% 4.19 77.2 947.2 1.74 20.2% 17,904 621.9 0.52
Mecklenburg‐Vorpommern 2004 6.4 1985.5 40% 15% 3.69 77.8 895.9 1.73 22.1% 18,450 681.2 0.46
Mecklenburg‐Vorpommern 2005 6.6 1985.7 42% 14% 3.83 78.0 882.1 1.71 21.3% 664.0 0.41
Mecklenburg‐Vorpommern 2006 6.7 1986.1 43% 15% 3.94 78.5 851.5 1.70 19.2% 19,193 707.9 0.24
Mecklenburg‐Vorpommern 2007 6.7 1986.4 45% 15% 3.98 78.7 843.5 1.69 17.4% 981.6 0.18
Mecklenburg‐Vorpommern 2008 7.0 1986.9 48% 16% 14.6%
Niedersachsen 2000 21.7 1982.6 30% 7% 2.74 78.0 884.6 7.91 6.6% 22,767 0.34
Niedersachsen 2001 23.1 1983.1 32% 9% 2.91 78.4 860.5 7.94 6.4% 22,904 257.0 0.43
Niedersachsen 2002 24.2 1983.5 34% 10% 3.04 78.4 860.7 7.97 7.2% 22,796 333.2 0.43
Niedersachsen 2003 25.6 1983.9 35% 11% 3.21 78.3 868.9 7.99 8.5% 22,965 277.3 0.43
Niedersachsen 2004 22.6 1984.3 37% 12% 2.82 79.0 815.2 8.00 9.5% 23,402 279.3 0.48













































































































































































































































































































































































































Niedersachsen 2006 23.5 1984.8 40% 12% 2.94 79.5 784.2 7.99 9.7% 24,897 311.4 0.41
Niedersachsen 2007 24.1 1985.2 42% 13% 3.03 79.7 771.6 7.98 7.9% 434.3 0.45
Niedersachsen 2008 25.0 1985.5 44% 14% 7.1%
Nordrhein‐Westfalen 2000 52.2 1983.0 31% 8% 1.51 77.9 906.3 18.00 6.5% 25,236 1.33
Nordrhein‐Westfalen 2001 54.7 1983.4 34% 10% 1.53 78.2 877.1 18.03 6.0% 25,622 242.7 1.20
Nordrhein‐Westfalen 2002 56.4 1983.7 35% 10% 1.61 78.2 880.9 18.06 7.2% 25,944 243.4 1.13
Nordrhein‐Westfalen 2003 59.1 1984.1 36% 11% 1.69 78.2 883.6 18.08 8.8% 26,073 232.4 1.15
Nordrhein‐Westfalen 2004 52.5 1984.5 38% 12% 1.50 78.8 840.3 18.07 9.5% 26,728 254.6 1.00
Nordrhein‐Westfalen 2005 53.6 1984.6 39% 11% 1.53 78.9 828.7 18.06 10.4% 290.9 1.01
Nordrhein‐Westfalen 2006 53.9 1984.9 40% 12% 1.54 79.4 799.7 18.04 9.8% 28,022 311.8 0.98
Nordrhein‐Westfalen 2007 55.3 1985.3 42% 12% 1.58 79.4 791.4 18.01 8.3% 493.6 0.92
Nordrhein‐Westfalen 2008 57.2 1985.6 44% 13% 7.4%
Rheinland‐Pfalz 2000 11.8 1983.2 33% 8% 2.94 78.1 885.0 4.03 5.8% 22,587 0.67
Rheinland‐Pfalz 2001 12.2 1983.7 35% 10% 3.03 78.4 867.5 4.04 5.0% 22,531 279.7 0.74
Rheinland‐Pfalz 2002 12.8 1984.0 36% 10% 3.16 78.5 865.3 4.05 5.6% 23,042 345.8 0.47
Rheinland‐Pfalz 2003 13.5 1984.2 37% 11% 3.32 78.4 879.7 4.06 6.3% 23,161 369.6 0.35
Rheinland‐Pfalz 2004 11.9 1984.7 39% 12% 2.94 79.2 819.3 4.06 7.0% 23,853 386.6 0.15
Rheinland‐Pfalz 2005 12.2 1984.9 41% 12% 3.02 79.2 818.6 4.06 8.7% 388.5 0.39
Rheinland‐Pfalz 2006 12.4 1985.3 42% 13% 3.06 79.7 786.9 4.05 8.0% 24,618 362.4 0.44
Rheinland‐Pfalz 2007 12.7 1985.7 44% 14% 3.14 79.8 774.7 4.05 6.0% 632.6 0.22
Rheinland‐Pfalz 2008 13.2 1986.1 47% 15% 5.6%
Saarland 2000 2.8 1983.0 32% 8% 2.62 77.1 961.9 1.07 7.3% 23,124 0.19
Saarland 2001 2.9 1983.6 34% 9% 2.76 77.3 946.2 1.07 5.9% 23,566 230.8 0.19
Saarland 2002 3.9 1984.0 36% 10% 3.69 77.6 937.4 1.07 7.6% 23,691 342.4 0.38
Saarland 2003 4.1 1984.3 37% 12% 3.87 77.1 960.9 1.06 8.3% 23,939 281.3 0.19
Saarland 2004 3.6 1984.8 39% 13% 3.40 78.2 886.3 1.06 8.7% 25,170 291.0
Saarland 2005 3.7 1984.9 41% 12% 3.49 78.3 886.3 1.05 10.8% 335.9
Saarland 2006 3.7 1985.3 42% 13% 3.51 78.4 867.4 1.05 9.5% 27,317 300.0
Saarland 2007 3.7 1985.7 45% 14% 3.52 78.7 852.5 1.04 7.3% 475.4
Saarland 2008 3.7 1986.1 47% 15% 7.1%
Sachsen 2000 15.6 1983.1 30% 8% 3.51 77.8 901.1 4.44 16.1% 17,032 0.14
Sachsen 2001 16.2 1983.8 33% 10% 3.67 78.4 860.3 4.40 17.0% 17,731 540.8 0.11
Sachsen 2002 16.6 1984.4 35% 12% 3.80 78.4 865.9 4.37 17.8% 18,632 733.9 0.14
Sachsen 2003 17.5 1985.0 37% 13% 4.04 78.4 868.4 4.33 17.8% 19,187 645.4 0.05
Sachsen 2004 15.5 1985.4 39% 14% 3.61 79.1 812.4 4.31 19.4% 19,860 698.9 0.05
Sachsen 2005 15.9 1985.7 41% 14% 3.71 79.3 801.3 4.28 18.7% 745.3 0.28
Sachsen 2006 16.3 1986.2 43% 15% 3.81 79.7 773.0 4.26 16.6% 20,747 716.0 0.16
Sachsen 2007 16.1 1986.6 45% 16% 3.81 79.7 772.0 4.23 14.4% 974.7 0.24













































































































































































































































































































































































































Sachsen‐Anhalt 2000 9.7 1982.7 30% 8% 3.68 76.5 1000.8 2.63 20.2% 16,437 0.19
Sachsen‐Anhalt 2001 9.9 1983.4 32% 10% 3.83 77.0 965.7 2.60 19.9% 16,937 561.9 0.23
Sachsen‐Anhalt 2002 10.2 1983.8 33% 11% 3.98 76.9 972.3 2.56 19.2% 17,848 680.5 0.08
Sachsen‐Anhalt 2003 10.9 1984.3 36% 13% 4.30 77.3 945.8 2.54 19.9% 18,165 554.6 0.32
Sachsen‐Anhalt 2004 9.6 1984.8 37% 14% 3.83 77.7 907.8 2.51 22.4% 18,758 500.2 0.32
Sachsen‐Anhalt 2005 9.8 1985.0 39% 13% 3.95 77.9 894.9 2.48 20.3% 574.8 0.20
Sachsen‐Anhalt 2006 9.9 1985.4 40% 14% 4.03 78.3 870.9 2.46 17.8% 20,057 540.2 0.33
Sachsen‐Anhalt 2007 10.0 1985.7 42% 15% 4.14 78.5 862.7 2.43 15.7% 813.1 0.12
Sachsen‐Anhalt 2008 10.4 1986.2 45% 16% 14.6%
Schleswig‐Holstein 2000 7.5 1983.0 33% 8% 2.69 78.1 881.9 2.78 6.4% 23,309 0.83
Schleswig‐Holstein 2001 7.7 1983.4 34% 10% 2.77 78.4 857.1 2.80 6.4% 23,775 265.6 0.89
Schleswig‐Holstein 2002 8.0 1983.7 35% 10% 2.83 78.6 848.2 2.81 7.6% 23,331 295.8 0.78
Schleswig‐Holstein 2003 8.4 1984.1 37% 11% 2.97 78.5 860.1 2.82 8.6% 23,540 267.0 1.10
Schleswig‐Holstein 2004 7.5 1984.4 38% 12% 2.64 78.9 824.8 2.83 9.7% 23,917 248.4 1.10
Schleswig‐Holstein 2005 7.6 1984.6 40% 11% 2.70 79.3 799.9 2.83 10.2% 262.5 0.95
Schleswig‐Holstein 2006 7.8 1985.0 41% 12% 2.74 79.6 784.2 2.83 9.0% 24,680 266.0 0.95
Schleswig‐Holstein 2007 8.0 1985.5 44% 13% 2.82 79.7 774.5 2.84 7.9% 378.3 0.63
Schleswig‐Holstein 2008 8.3 1985.8 45% 14% 6.8%
Thueringen 2000 7.6 1983.0 30% 8% 3.12 77.3 965.3 2.44 13.5% 16,638 0.04
Thueringen 2001 7.8 1983.7 33% 10% 3.20 77.7 926.1 2.42 13.9% 17,211 490.5
Thueringen 2002 9.2 1984.3 35% 11% 3.84 77.8 927.1 2.40 15.1% 17,666 662.9 0.08
Thueringen 2003 9.8 1984.9 37% 13% 4.11 77.8 926.3 2.38 16.3% 18,223 541.1 0.04
Thueringen 2004 8.6 1985.4 39% 14% 3.65 78.3 872.1 2.36 16.3% 18,878 661.0
Thueringen 2005 8.9 1985.7 40% 13% 3.79 78.7 859.7 2.35 17.1% 612.3 0.04
Thueringen 2006 9.1 1986.1 42% 15% 3.91 78.8 840.0 2.32 15.6% 19,877 677.8 0.13
Thueringen 2007 9.0 1986.4 44% 15% 3.92 79.1 827.0 2.30 13.7% 872.6





















ALL 2002 0.45 7 1975.3 14% 14%
ALL 2003 0.43 3 2001.0 100% 100%
ALL 2004 0.39 14 1998.9 93% 93%
ALL 2005 0.34 16 1987.9 56% 56%
ALL 2006 0.40 19 1986.8 53% 53%
AML 2003 2.32 1 2001.0 100% 100%
AML 2005 2.40 2 2001.0 100% 100%
AML 2006 2.27 1 2001.0 100% 100%
BLADDER 2002 7.17 32 1993.4 84% 84%
BLADDER 2003 7.53 40 1991.2 63% 63%
BLADDER 2004 7.41 59 1993.1 80% 80%
BLADDER 2005 7.46 71 1992.0 70% 70%
BLADDER 2006 7.19 75 1991.5 65% 65%
BRAIN 2002 4.74 37 1998.8 97% 97%
BRAIN 2003 4.82 46 1997.5 89% 89%
BRAIN 2004 4.58 80 1996.9 85% 85%
BRAIN 2005 4.52 148 1997.1 86% 86%
BRAIN 2006 4.50 150 1997.0 86% 86%
BREAST 2002 19.03 664 1986.2 36% 27%
BREAST 2003 18.68 792 1986.2 37% 28%
BREAST 2004 18.50 926 1986.5 35% 30%
BREAST 2005 18.31 1300 1987.5 42% 38%
BREAST 2006 17.99 1345 1987.8 43% 39%
CERVIX UTERI 2005 1.18 1 1984.0 0% 0%
CERVIX UTERI 2006 1.10 1 1984.0 0% 0%
CLL 2002 1.83 31 1971.0 0% 0%
CLL 2003 1.90 28 1972.1 4% 4%
CLL 2004 1.79 23 1971.0 0% 0%
CLL 2005 1.71 28 1971.0 0% 0%
CLL 2006 1.75 36 1971.0 0% 0%
CML 2002 0.93 89 2001.0 100% 100%
CML 2003 0.95 112 2001.0 100% 100%
CML 2004 0.89 126 2001.0 100% 100%
CML 2005 0.92 163 2001.0 100% 100%
CML 2006 0.76 158 2001.0 100% 100%
COLORECTAL 2002 27.03 22 1998.0 100% 100%
COLORECTAL 2003 27.16 45 1998.0 100% 100%
COLORECTAL 2004 26.68 53 1998.2 100% 100%
COLORECTAL 2005 26.33 108 1998.0 100% 100%
COLORECTAL 2006 25.20 104 1998.1 100% 100%
CORPUS UTERI 2002 0.89 16 1988.5 50% 50%
CORPUS UTERI 2003 0.99 11 1989.5 64% 64%
CORPUS UTERI 2004 0.90 20 1988.2 45% 45%
CORPUS UTERI 2005 1.02 25 1988.6 52% 52%
CORPUS UTERI 2006 0.93 22 1988.5 50% 50%





















HEAD & NECK 2003 7.35 62 1987.2 32% 31%
HEAD & NECK 2004 6.95 55 1986.7 22% 18%
HEAD & NECK 2005 6.72 105 1988.7 42% 39%
HEAD & NECK 2006 6.35 108 1988.8 43% 40%
HODGKINS DISEASE 2002 0.46 88 1971.4 2% 0%
HODGKINS DISEASE 2003 0.46 132 1971.4 2% 0%
HODGKINS DISEASE 2004 0.48 201 1971.5 3% 0%
HODGKINS DISEASE 2005 0.44 208 1971.5 3% 0%
HODGKINS DISEASE 2006 0.43 205 1971.9 5% 0%
KIDNEY 2003 5.17 3 1971.0 0% 0%
KIDNEY 2004 4.91 5 1971.0 0% 0%
KIDNEY 2005 4.94 6 1971.0 0% 0%
KIDNEY 2006 4.80 6 1971.0 0% 0%
LIVER 2002 11.63 38 1993.1 92% 92%
LIVER 2003 11.66 47 1993.3 91% 91%
LIVER 2004 11.48 42 1995.3 100% 100%
LIVER 2005 11.65 55 1989.4 71% 71%
LIVER 2006 11.55 61 1990.1 75% 75%
LUNG 2002 41.89 533 1990.6 80% 47%
LUNG 2003 42.98 724 1990.8 79% 48%
LUNG 2004 43.22 739 1991.4 83% 57%
LUNG 2005 44.09 1080 1991.6 78% 56%
LUNG 2006 43.81 1194 1991.5 77% 54%
M.MYELOMA & MALIG PLAS 2002 3.92 85 1971.0 0% 0%
M.MYELOMA & MALIG PLAS 2003 4.07 69 1971.0 0% 0%
M.MYELOMA & MALIG PLAS 2004 3.73 79 1971.0 0% 0%
M.MYELOMA & MALIG PLAS 2005 3.79 83 1971.0 0% 0%
M.MYELOMA & MALIG PLAS 2006 3.73 85 1971.3 1% 1%
MELANOMA 2002 2.32 3 1999.0 100% 100%
MELANOMA 2003 2.36 2 1999.0 100% 100%
MELANOMA 2004 2.32 3 1996.7 100% 100%
MELANOMA 2005 2.41 10 1996.6 100% 90%
MELANOMA 2006 2.41 8 1995.1 100% 88%
NHL 2002 7.19 303 1971.9 0% 0%
NHL 2003 6.81 361 1971.6 1% 1%
NHL 2004 6.65 455 1971.7 0% 0%
NHL 2005 6.56 553 1972.2 2% 2%
NHL 2006 6.22 573 1972.3 3% 2%
OESOPHAGUS 2002 6.99 10 1987.9 50% 10%
OESOPHAGUS 2003 6.59 7 1986.1 29% 0%
OESOPHAGUS 2004 6.23 11 1986.3 18% 9%
OESOPHAGUS 2005 6.22 23 1989.5 61% 39%
OESOPHAGUS 2006 5.94 26 1989.9 62% 42%
OVARIAN 2002 5.53 226 1988.5 48% 48%
OVARIAN 2003 5.35 231 1988.5 48% 48%





















OVARIAN 2005 5.27 398 1988.4 47% 47%
OVARIAN 2006 5.17 366 1988.4 47% 47%
PANCREAS 2002 12.44 106 1995.0 99% 99%
PANCREAS 2003 12.25 130 1995.0 100% 100%
PANCREAS 2004 12.52 180 1994.9 99% 99%
PANCREAS 2005 12.76 200 1995.0 99% 99%
PANCREAS 2006 12.74 203 1994.9 99% 99%
PROSTATE 2002 15.53 23 1994.7 100% 96%
PROSTATE 2003 15.64 36 1993.2 100% 69%
PROSTATE 2004 14.87 58 1993.9 100% 81%
PROSTATE 2005 14.46 60 1994.8 100% 97%
PROSTATE 2006 13.64 69 1994.8 100% 97%
STOMACH 2002 8.57 19 1986.5 21% 21%
STOMACH 2003 8.04 12 1990.1 42% 42%
STOMACH 2004 8.03 18 1993.4 72% 72%
STOMACH 2005 7.69 52 1994.2 75% 75%
STOMACH 2006 7.35 51 1993.2 69% 69%
THYROID 2005 0.62 2 1993.5 100% 100%
THYROID 2006 0.67 2 1993.5 100% 100%
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